Strong Financial Performance in 2024
Sofwave Medical Ltd (TASE: SOFW), a pioneering company in the non-invasive aesthetic medical device sector, recently reported impressive preliminary financial results for the fourth quarter and the entire fiscal year. With products that enhance treatments for practitioners globally, Sofwave truly stands out in the market.
Fourth Quarter Highlights
The company anticipates its revenue for the fourth quarter of 2024 to fall between $18.2 million and $18.4 million, marking a remarkable growth of approximately 20% compared to roughly $15.3 million during the same period in 2023. This growth reflects the increasing demand for its innovative aesthetic technologies.
Full Fiscal Year Performance
In terms of overall fiscal performance, Sofwave expects its total revenue for the full year 2024 to be between $59.5 million and $59.7 million, an expansion from $50.3 million in the previous year, indicating a steady rise of about 19%. This upward trend showcases the company’s effectiveness in catering to the expanding market for aesthetic medical devices.
Financial Stability
As of December 31, 2024, Sofwave reported approximately $21.6 million in cash and cash equivalents, a slight increase from $21.2 million on September 30, 2024. This demonstrates the company's solid financial management and ability to sustain growth amidst rising operational demands.
About Sofwave Medical
Sofwave Medical Ltd, known for its revolutionary approach to wrinkle reduction and skin lifting procedures, leverages its proprietary SUPERB™ technology. This Synchronous Ultrasound Parallel Beam technology, which has received FDA clearance, effectively addresses facial wrinkles and improves skin laxity in various areas, including beneath the chin and on the upper arms. The innovative Pure Impact™ module uses electrical muscle stimulation technology approved for muscle toning, offering practitioners safe and effective treatment options.
Contact Information
For further inquiries, you can reach out to Sofwave Medical or their investor relations team. Interested parties may contact:
General Contact
Email: Info@sofwave.com
Investor Relations
Brian Ritchie
LifeSci Advisors LLC
(212) 915-2578
Email: britchie@lifesciadvisors.com
Frequently Asked Questions
What is Sofwave Medical known for?
Sofwave Medical specializes in non-invasive aesthetic medical devices that improve skin quality and appearance.
What were Sofwave's revenue expectations for 2024?
For 2024, Sofwave expects its revenue to be between $59.5 million and $59.7 million.
How much cash did Sofwave have at the end of 2024?
As of December 31, 2024, Sofwave reported approximately $21.6 million in cash and cash equivalents.
What technology does Sofwave utilize in its treatments?
Sofwave uses its patented SUPERB™ technology, which is FDA-cleared for various aesthetic treatments.
Who can I contact for more information about Sofwave?
You can contact Sofwave's general information email at Info@sofwave.com or reach out to their investor relations via Brian Ritchie from LifeSci Advisors LLC.